| $385M | ||
| $350M | ||
| $215M | ||
| $88M | ||
| $82M | ||
| $62M |
Buys | $0 | 0 | 0 |
Sells | $23,701,519 | 15 | 100 |
| Harmon Cyrus | director | 0 | $0 | 5 | $657,435 | $-657,435 |
| Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OFF. | 0 | $0 | 2 | $2.98M | $-2.98M |
| Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | 0 | $0 | 4 | $4.66M | $-4.66M |
| Zojwalla Naseem | Chief Medical Officer | 0 | $0 | 3 | $7.53M | $-7.53M |
| CLARK IAN T | director | 0 | $0 | 1 | $7.87M | $-7.87M |
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Over the last 12 months, insiders at Olema Pharmaceuticals, Inc. have bought $0 and sold $23.7M worth of Olema Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Olema Pharmaceuticals, Inc. have bought $10.3M and sold $20.28M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 300,000 shares for transaction amount of $1.73M was made by Bain Capital Life Sciences Investors, LLC (10 percent owner) on 2025‑01‑08.
| 2026-01-20 | Sale | Harmon Cyrus | director | 10,000 0.0128% | $26.88 | $268,800 | -4.41% | |
| 2026-01-15 | Sale | Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OFF. | 100,000 0.1433% | $28.73 | $2.87M | -12.16% | |
| 2026-01-14 | Sale | Harmon Cyrus | director | 3,489 0.0051% | $29.12 | $101,600 | -10.78% | |
| 2026-01-14 | Sale | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | 50,000 0.0731% | $28.87 | $1.44M | -10.78% | |
| 2026-01-13 | Sale | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | 50,000 0.0721% | $27.60 | $1.38M | -7.85% | |
| 2026-01-13 | Sale | Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OFF. | 3,822 0.0056% | $28.01 | $107,054 | -7.85% | |
| 2026-01-12 | Sale | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | 10,000 0.0143% | $28.34 | $283,400 | -10.71% | |
| 2025-12-23 | Sale | Zojwalla Naseem | Chief Medical Officer | 99,509 0.1423% | $27.66 | $2.75M | -7.23% | |
| 2025-12-22 | Sale | Harmon Cyrus | director | 2,881 0.0042% | $28.53 | $82,195 | -8.80% | |
| 2025-12-22 | Sale | Zojwalla Naseem | Chief Medical Officer | 100,000 0.1449% | $28.04 | $2.8M | -8.80% | |
| 2025-12-19 | Sale | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | 51,000 0.081% | $30.46 | $1.55M | -7.96% | |
| 2025-12-19 | Sale | Zojwalla Naseem | Chief Medical Officer | 70,000 0.1029% | $28.20 | $1.97M | -7.96% | |
| 2025-12-19 | Sale | CLARK IAN T | director | 264,800 0.4105% | $29.73 | $7.87M | -7.96% | |
| 2025-09-18 | Sale | Harmon Cyrus | director | 13,086 0.0187% | $8.33 | $108,976 | +188.72% | |
| 2025-09-16 | Sale | Harmon Cyrus | director | 11,914 0.0177% | $8.05 | $95,865 | +207.10% | |
| 2025-01-08 | Bain Capital Life Sciences Investors, LLC | 10 percent owner | 300,000 0.395% | $5.76 | $1.73M | -8.09% | ||
| 2024-12-17 | Sale | Graham G. Walmsley | director | 700,761 1.3522% | $6.75 | $4.73M | -14.01% | |
| 2024-12-17 | Graham G. Walmsley | director | 700,761 1.3522% | $6.75 | $4.73M | -14.01% | ||
| 2024-12-13 | Sale | Graham G. Walmsley | director | 700,761 1.2508% | $6.75 | $4.73M | -21.78% | |
| 2024-12-13 | Graham G. Walmsley | director | 700,761 1.2508% | $6.75 | $4.73M | -21.78% |
| Harmon Cyrus | director | 727770 0.9252% | $16.46M | 0 | 40 | |
| Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | 542761 0.69% | $12.28M | 0 | 14 | |
| Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OFF. | 139727 0.1776% | $3.16M | 2 | 6 | +243.62% |
| Zojwalla Naseem | Chief Medical Officer | 4488 0.0057% | $101,518.56 | 0 | 7 | |
| CLARK IAN T | director | 0 0% | $0 | 0 | 1 | |
| Bain Capital Life Sciences Investors, LLC | 10 percent owner | 7800000 9.9161% | $176.44M | 1 | 0 | <0.0001% |
| BVF PARTNERS L P/IL | 4688954 5.961% | $106.06M | 3 | 0 | <0.0001% | |
| Cormorant Asset Management, LP | 3270544 4.1578% | $73.98M | 1 | 0 | <0.0001% | |
| LAMPERT MARK N | 2906659 3.6952% | $65.75M | 1 | 0 | <0.0001% | |
| Graham G. Walmsley | director | 1408875 1.7911% | $31.87M | 5 | 3 | <0.0001% |
| Paradigm Biocapital Advisors LP | 10 percent owner | 783118 0.9956% | $17.71M | 1 | 1 | +0.94% |
| Bohen Sean | PRESIDENT AND CEO | 241662 0.3072% | $5.47M | 0 | 9 | |
| Horn Kinney | CHIEF BUSINESS OFFICER | 2458 0.0031% | $55,599.96 | 0 | 10 |
$831,902,292 | 108 | 9.34% | $1.7B | |
$607,159,124 | 92 | 3.55% | $1.57B | |
$1,103,317,478 | 60 | 36.54% | $1.64B | |
$47,419,530 | 58 | 17.20% | $1.87B | |
$1,376,668 | 53 | 18.46% | $1.86B | |
$571,084,134 | 44 | 4.33% | $1.94B | |
$62,927,079 | 29 | 14.02% | $2.07B | |
$82,281,805 | 29 | -1.52% | $1.73B | |
$25,045,414 | 23 | -3.79% | $2.01B | |
$8,195,601 | 23 | -12.08% | $2.08B | |
$12,094,896 | 19 | 20.07% | $1.89B | |
$154,554,190 | 14 | 29.60% | $1.63B | |
Olema Pharmaceuticals, Inc. (OLMA) | $144,557,026 | 13 | 0.49% | $1.78B |
$94,976,497 | 10 | -10.72% | $1.78B | |
$2,859,892 | 10 | 29.21% | $1.77B | |
$93,268,646 | 8 | -37.22% | $1.55B | |
$4,623,072 | 7 | 11.07% | $1.95B | |
$3,200,000 | 5 | -11.36% | $1.59B | |
$7,605,533 | 5 | 17.10% | $1.85B |
| Increased Positions | 108 | +85.71% | 14M | +20.2% |
| Decreased Positions | 53 | -42.06% | 17M | -23.46% |
| New Positions | 57 | New | 10M | New |
| Sold Out Positions | 15 | Sold Out | 7M | Sold Out |
| Total Postitions | 181 | +43.65% | 69M | -3.26% |
| Bain Capital Life Sciences Investors, Llc | $173,015.00 | 8.66% | 6.84M | 0 | 0% | 2025-09-30 |
| Paradigm Biocapital Advisors Lp | $171,757.00 | 8.6% | 6.79M | +30,000 | +0.44% | 2025-09-30 |
| Bvf Inc/Il | $133,880.00 | 6.7% | 5.3M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $119,483.00 | 5.98% | 4.73M | +121,285 | +2.63% | 2025-09-30 |
| Janus Henderson Group Plc | $90,650.00 | 4.54% | 3.59M | +563,065 | +18.63% | 2025-09-30 |
| Deep Track Capital, Lp | $87,726.00 | 4.39% | 3.47M | +27,339 | +0.79% | 2025-09-30 |
| Logos Global Management Lp | $81,120.00 | 4.06% | 3.21M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $80,828.00 | 4.05% | 3.2M | -69,679 | -2.13% | 2025-09-30 |
| Franklin Resources Inc | $76,143.00 | 3.81% | 3.01M | 0 | 0% | 2025-09-30 |
| Woodline Partners Lp | $56,068.00 | 2.81% | 2.22M | -1M | -36.74% | 2025-09-30 |